echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The domestic recombinant insulin Qixiong contends for hegemony, the new force launches new challenges!

    The domestic recombinant insulin Qixiong contends for hegemony, the new force launches new challenges!

    • Last Update: 2021-09-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In July, the National Medical Insurance Bureau held a working forum to listen to the opinions and suggestions of relevant companies and industry associations on the reform of centralized insulin procurement



    According to the annual reports of multinational companies, the global insulin market will exceed US$21.




    From 2018 to 2020, the proportion of imported brands only dropped by 1.


    In the bargaining of the quantity of insulin drugs in Wuhan in 2020, centralized procurement has promoted the changes in the market structure, reflecting the trend of accelerating the substitution of imported insulin by domestically produced insulin and controlling the excessive growth of medical expenses


    Domestic recombinant insulin is eye-catching


    From January to July 2021, the NMPA approved 10 insulin production approval documents produced by domestic companies, which is double the number of approvals for the entire year of 2020




    Insulin aspart belongs to the third generation of insulin.


    According to data from Minai.




    In 2020, Sanofi's total sales of insulin glargine (Lantus, Toujeo) was 3.


    In 2002, Sanofi's insulin glargine entered the Chinese market under the trade name Laidushi
    .
    In 2005, Beijing Ganli Pharmaceutical’s Chang Xiulin was approved for production; Zhuhai Federation’s insulin glargine was approved in 2016 under the trade name You Le Ling; Tonghua Dongbao Pharmaceutical’s insulin glargine was approved at the end of 2019, under the trade name Chang Shu Lin
    .
    In January 2020, Chang Shulin completed the production and inspection of multiple batches, and began to put on the market in February 2020
    .

    According to data from Minai.
    com, in 2020, the sales of insulin glargine injection in China's public medical institutions will exceed 6.
    8 billion yuan, a year-on-year increase of 12.
    88%
    .
    In the past 10 years, insulin glargine injection has maintained a growth trend
    .
    In the first quarter of 2021, Sanofi’s Insulin Glargine injection market in public hospitals in key provinces and municipalities accounted for 73.
    02%, Chang Xiulin of Ganli Pharmaceuticals accounted for 25.
    18%, and Youlerin of Zhuhai Federation accounted for 1.
    81%
    .
    The share of domestic drugs in the market is increasing year by year
    .

      
      Ganli Pharmaceutical’s recombinant insulin glargine injection, Chang Xiulin, has been singing in the insulin market all the way, promoting Ganli Pharmaceutical’s official landing on the Shanghai Stock Exchange in 2020
    .
    In 2020, Chang Xiulin's terminal sales in China's public medical institutions were 2.
    559 billion yuan, an increase of 15.
    46% year-on-year, and it accounted for more than one-third of the domestic insulin glargine injection market share
    .
    The company has recombinant insulin lispro (fast-acting), recombinant insulin glargine (long-acting), insulin aspart and protamine zinc, recombinant insulin lispro (25R), insulin aspart 30 and protamine-human insulin mixed (30R), etc.
    6 This product has become a leading company in the domestic insulin industry
    .
      

    Postscript <<<

      

      Since the advent of insulin, it has experienced the development process from the first generation to the third generation, from animal insulin to human insulin, and then to recombinant human insulin analogues
    .
    With the decrease in the amount of animal insulin, some manufacturers have revoked production approvals.
    In 2020, there are only 9 animal insulin injection approvals, a 58% decrease from 21 in 2013
    .
      

      A variety of new varieties have attracted the attention of domestic companies.
    At present, the number of manufacturers entering the insulin industry has increased year by year.
    The domestic reorganized insulin industry has become a situation where seven heroes are competing for hegemony, and the latecomers are launching new challenges
    .
    Beijing Shuanglu Pharmaceutical, Chongqing Chen'an Biopharmaceutical, Zhengda Tianqing Pharmaceutical, Zhejiang Hisun Pharmaceutical, Jilin Huisheng Biopharmaceutical, Huaangde Biopharmaceutical, Shandong New Times Pharmaceutical, Lanzhou Biological Products Research Institute, Dongguan New products from 9 companies including Shidong Sunshine Biopharmaceutical R&D are under review and approval
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.